Showing 6851-6860 of 9552 results for "".
- Industry Responds to COVID-19: Allergan Foundation; AG Hair; Revancehttps://practicaldermatology.com/news/industry-responds-to-covid-19-allergan-foundation-ag-hair-revance/2460326/Allergan. Of the approximately $13 million in charitable grants the Allergan Foundation has awarded in 2020, a total of $2 million will be dedicated to more than 70 organizations responding to the local impact of the COVID-19 pandemic. Other grant recipients i
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugshttps://practicaldermatology.com/news/covid-19-update-aad-others-react-to-potential-shortage-of-malaria-and-arthritis-drugs-1/2460320/The American Academy of Dermatology along with the Lupus Foundation of America, the American College of Rheumatology, and the Arthritis Foundation are concerned about hydroxychloroquine and chloroquine shortages and how it will impact patients with autoimmune diseases. The groups sent a
- Pfizer's Abrocitinib Improves Atopic Dermatitis in Phase 3 Studyhttps://practicaldermatology.com/news/pfizers-abrocitinib-improves-atopic-dermatitis-in-phase-3-study/2460316/Top-line Results from a third Phase 3 trial of Pfizer's abrocitinib for moderate to severe atopic dermatitis showed improvements in skin
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- Dermatologist Urges Vigilance for Exanthem as Coronavirus Spreadshttps://practicaldermatology.com/news/dermatologist-urges-vigilance-for-exanthem-as-coronavirus-spreads/2460304/As the novel coronavirus spreads across the US and the World Health Organization declares a global pandemic, dermatologists may be able to play a role in diagnosing and combating the disease, says New York City dermatologist Bobby Buka, MD, JD. In fact, the cofounder of The Dermatology Specialist
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Aesthetics Biomedical Taps Molly Sims As New SoME Skincare Brand Ambassadorhttps://practicaldermatology.com/news/aesthetics-biomedical-taps-molly-sims-as-new-some-skincare-brand-ambassador/2460290/Molly Sims is Brand Ambassador for Aesthetics Biomedical’s SoME Skincare That's All You, a patented personalized Platelet Rich Plasma (PRP) skincare for at-home use. SoME That's All You is com
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Resident of Distinction Award Celebrates 10th Anniversary at 2020 Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/resident-of-distinction-award-celebrates-10th-anniversary-at-2020-caribbean-dermatology-symposium/2460276/As part of the dermMentors Resident of Distinction Award, Beiersdorf Inc. sponsored five top dermatology residents to attend the 2020 Caribbean Dermatology Symposium, held in Paradise Island, Bahamas, from Jan. 21-25, 2020.